NCT05273554: A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma

Sponsor: M.D. Anderson Cancer Center. Phase: PHASE1. Conditions: Tumor, Adenocarcinoma